Clinical trial
Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer
NCT00003551 · Emory University, Other · Completed
Key facts
| NCT number | NCT00003551 |
|---|---|
| Title | Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer |
| Official title | A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Emory University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | aminocamptothecin colloidal dispersion |
| Start date | Aug 1, 1998 |
| Completion | Sep 1, 2004 |
| First posted | Sep 13, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: